Johnson & Johnson (JNJ) has gained significant traction in 2026, achieving an all-time high of $269 per share. The healthcare giant will release its Q2 earnings report on Wednesday, July 15, with analysts expecting an earnings per share (EPS) of approximately $2.85 on revenues of $25.18 billion, reflecting year-over-year growth of 3% and 6%, respectively.
Investors will focus on JNJ’s Innovative Medicine segment, especially sales from cancer therapies like Darzalex, and momentum in its MedTech business. JNJ’s valuation is favorable, trading at 22 times forward earnings, which is slightly under the S&P 500 benchmark. The company’s robust dividend yield of 2.09% aligns with its strong cash flows and consistent earnings growth.
As JNJ prepares for its Q2 release, strong performance could further elevate stock value amid increasing investor interest in high-quality defensive stocks during the earnings season. Historically, JNJ has had an average EPS surprise of 1.89% over its last four reports.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
